These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25559739)

  • 1. Vaccines in the treatment of invasive candidiasis.
    Wang XJ; Sui X; Yan L; Wang Y; Cao YB; Jiang YY
    Virulence; 2015; 6(4):309-15. PubMed ID: 25559739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of antigen delivery using monoolein-based liposomes in experimental hematogenously disseminated candidiasis.
    Carneiro C; Correia A; Lima T; Vilanova M; Pais C; Gomes AC; Real Oliveira MECD; Sampaio P
    Acta Biomater; 2016 Jul; 39():133-145. PubMed ID: 27150234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active immunizations with peptide-DC vaccines and passive transfer with antibodies protect neutropenic mice against disseminated candidiasis.
    Xin H
    Vaccine; 2016 Jan; 34(2):245-251. PubMed ID: 26620842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.
    Saville SP; Lazzell AL; Chaturvedi AK; Monteagudo C; Lopez-Ribot JL
    Clin Vaccine Immunol; 2009 Mar; 16(3):430-2. PubMed ID: 19144791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Intravenous Immunoglobulin Therapy for the Prevention and Treatment of Candida auris and Candida albicans Disseminated Candidiasis.
    Xin H; Rosario-Colon JA; Eberle K
    mSphere; 2023 Feb; 8(1):e0058422. PubMed ID: 36688668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive immune responses to Candida albicans infection.
    Richardson JP; Moyes DL
    Virulence; 2015; 6(4):327-37. PubMed ID: 25607781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis.
    Xin H; Glee P; Adams A; Mohiuddin F; Eberle K
    Vaccine; 2019 Apr; 37(18):2430-2438. PubMed ID: 30930005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of vaccines for Candida albicans: fighting a skilled transformer.
    Cassone A
    Nat Rev Microbiol; 2013 Dec; 11(12):884-91. PubMed ID: 24232568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis.
    Luo G; Ibrahim AS; French SW; Edwards JE; Fu Y
    PLoS One; 2011; 6(10):e25909. PubMed ID: 22028796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel Th cell epitope of Candida albicans mediates protection from fungal infection.
    Bär E; Gladiator A; Bastidas S; Roschitzki B; Acha-Orbea H; Oxenius A; LeibundGut-Landmann S
    J Immunol; 2012 Jun; 188(11):5636-43. PubMed ID: 22529294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective antigens and mechanisms of anti-Candida immunity.
    Antonio C
    Nihon Ishinkin Gakkai Zasshi; 2000; 41(4):219. PubMed ID: 11064318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis.
    Han Y; Rhew KY
    Arch Pharm Res; 2012 Nov; 35(11):2021-7. PubMed ID: 23212645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Looking into Candida albicans infection, host response, and antifungal strategies.
    Wang Y
    Virulence; 2015; 6(4):307-8. PubMed ID: 25590793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing Antifungal Vaccines in an Animal Model of Invasive Candidiasis and in Human Mucosal Candidiasis.
    Segal E
    Methods Mol Biol; 2017; 1625():343-353. PubMed ID: 28585001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidiasis: a fungal infection--current challenges and progress in prevention and treatment.
    Hani U; Shivakumar HG; Vaghela R; Osmani RA; Shrivastava A
    Infect Disord Drug Targets; 2015; 15(1):42-52. PubMed ID: 25809621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine.
    Bromuro C; Torosantucci A; Chiani P; Conti S; Polonelli L; Cassone A
    Infect Immun; 2002 Oct; 70(10):5462-70. PubMed ID: 12228271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida vaginitis: virulence, host response and vaccine prospects.
    De Bernardis F; Graziani S; Tirelli F; Antonopoulou S
    Med Mycol; 2018 Apr; 56(suppl_1):26-31. PubMed ID: 29538739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is a vaccine needed against Candida albicans?
    Mochon AB; Cutler JE
    Med Mycol; 2005 Mar; 43(2):97-115. PubMed ID: 15832554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico Design of a Multivalent Vaccine Against Candida albicans.
    Tarang S; Kesherwani V; LaTendresse B; Lindgren L; Rocha-Sanchez SM; Weston MD
    Sci Rep; 2020 Jan; 10(1):1066. PubMed ID: 31974431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A β-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits.
    Lipinski T; Wu X; Sadowska J; Kreiter E; Yasui Y; Cheriaparambil S; Rennie R; Bundle DR
    Vaccine; 2012 Sep; 30(44):6263-9. PubMed ID: 22902677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.